Multiple sclerosis

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Inflammasome, Obesity, Entrepreneurship, Multiple sclerosis, Inflammation, Death, NLRP3, World Health Organization, ASC, Therapy, Atherosclerosis, Drug development, Pharmaceutical industry

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.

Key Points: 
  • According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.
  • WESTON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in a panel discussion titled “Inflammation Illuminated,” at Benzinga’s Virtual Healthcare Summit 2024.
  • He will also address new innovations in drug development to alleviate damaging inflammation.
  • Details regarding Mr. Glover’s panel discussion are as follows:

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

Registration Opens for the National Association of Specialty Pharmacy 2024 Annual Meeting & Expo

Retrieved on: 
Tuesday, March 12, 2024
Convention center, Pharmacist, Annual, Organ transplantation, Rheumatoid arthritis, CE, Woman, Multiple sclerosis, Haemophilia, Pharmacy, Patient, Cancer, Abstract, Love, Specialty pharmacy, National Association, CSP, Cell, Data management, Nursing, Education, NASP, Consultant, Cystic fibrosis, Accreditation, Hospital

Washington, DC, March 12, 2024 (GLOBE NEWSWIRE) -- Today, the National Association of Specialty Pharmacy (NASP), the only industry association in the U.S. whose membership includes all specialty pharmacy stakeholders, opened registration for the NASP 2024 Annual Meeting & Expo, to be held October 6 - 9, 2024, at the Gaylord Opryland Resort & Convention Center in Nashville, TN.

Key Points: 
  • Washington, DC, March 12, 2024 (GLOBE NEWSWIRE) -- Today, the National Association of Specialty Pharmacy (NASP), the only industry association in the U.S. whose membership includes all specialty pharmacy stakeholders, opened registration for the NASP 2024 Annual Meeting & Expo, to be held October 6 - 9, 2024, at the Gaylord Opryland Resort & Convention Center in Nashville, TN.
  • “The NASP 2024 Annual Meeting & Expo offers everything that attendees have come to love and expect, including top-of-class educational content and networking events.
  • Workshops include Accreditation, Cell & Gene Therapy, Certified Specialty Pharmacist (CSP) Exam Prep Course, Hospital/Health System Specialty Pharmacy, Specialty Pharmacy Law, and Technology.
  • The Annual Meeting & Expo also features a showcase for specialty pharmacy clinical research with its abstract and poster program.

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Retrieved on: 
Tuesday, March 12, 2024
CELU, Annual, Weill Cornell Medicine, Medical device, SBMT, Congress, Dementia, Innovation Park, Brain mapping, WBMF, Multiple sclerosis, Immunotherapy, Patient, Brain, Nanotechnology, Cancer, AI, Cell therapy, Society, Neurosurgery, Regenerative medicine, Therapy, DSM-IV codes, Cell, Virtual reality, Pharmaceutical industry

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Key Points: 
  • FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
  • Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
  • Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
  • SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Retrieved on: 
Monday, April 1, 2024
Health, Neurology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SVB Securities, Bankruptcy, Neurotoxin, Multiple sclerosis, Patient, King & Spalding, Merz, Sale, Perella Weinberg Partners, LLP, Security (finance), United States bankruptcy court, Morgan Stanley, Ernst & Young, DSM-IV codes, Therapy, Acorda Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
  • Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany.
  • The decision to file for Chapter 11 protection follows a lengthy strategic review during which the Company explored a wide range of strategic options.
  • Upon court approval, Acorda expects to minimize the impact of the bankruptcy process on its employees, customers, patients, and other key stakeholders.

Octave Bioscience Accelerates Leadership in Precision Care for Neurodegenerative Diseases with Addition of World-Class Commercial Executives

Retrieved on: 
Thursday, March 28, 2024
Neurology, Biotechnology, General Health, Health, Artificial Intelligence, Medical Devices, Technology, Other Health, Growth, Multiple sclerosis, Physician, Patient, COE, Biomarker, AI, Jeron, CPT, Drug development, Pharmaceutical industry

Octave recently appointed CEO Doug Biehn, who brings over 20 years of healthcare experience building and scaling growth businesses.

Key Points: 
  • Octave recently appointed CEO Doug Biehn, who brings over 20 years of healthcare experience building and scaling growth businesses.
  • Additionally, Octave recently expanded its precision care platform beyond multiple sclerosis into Parkinson’s with a $10 million grant from The Michael J.
  • Prior to joining Octave, Jeron built and scaled world-class commercial teams resulting in new standards of care and three successful acquisitions.
  • "Joining Octave means getting the chance to make a real difference in the lives of patients with neurodegenerative diseases,” said Debbie Ledet.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease

Retrieved on: 
Tuesday, March 26, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neurology, Multiple sclerosis, Biomarker, Neuroscience, Parkinson's disease, Biogen, Safety, LUMA, Medtech, Medical imaging

Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.

Key Points: 
  • Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
  • As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
  • In addition, Biogen and Indivi aim to develop and validate novel digital endpoints in Parkinson’s disease as well as explore additional disease areas for endpoint development leveraging KonectomTM.
  • Indivi uses advanced computational and statistical modelling methods to potentially yield more precise measures of progression of Parkinson’s disease with improved signal-to-noise properties.

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Retrieved on: 
Tuesday, March 26, 2024
Professional Services, Health, Neurology, Finance, Pharmaceutical, Biotechnology, AbbVie, MRI, AstraZeneca, Actelion, Disease, Multiple sclerosis, Ponesimod, Partnership, Novartis, Patient, RMS, Acquisition, DMT, Woman, Johnson & Johnson, Patent, Fatigue, Marketing, Pharmaceutical industry

To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals.

Key Points: 
  • To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals.
  • “We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals.
  • Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients.
  • Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.

The Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation

Retrieved on: 
Saturday, March 23, 2024
Science, Neurology, Software, Research, Health, Data Management, Health Technology, Technology, MSIN, Acceleration, Learning, Multiple sclerosis, 1-Click, Dell Medical School, Sclerosis, MSAA, Doctor of Philosophy, MD, University, Implementation Science, Novartis, Population health, Multimedia, Medical director, Nursing

SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.

Key Points: 
  • SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.
  • SEQSTER unifies people living with multiple sclerosis (MS), researchers, and care centers nationwide.
  • View the full release here: https://www.businesswire.com/news/home/20240321509514/en/
    Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation (Graphic: Business Wire)
    This announcement follows the creation of the Multiple Sclerosis Implementation Network™ (MSIN™), which MSAA launched in collaboration with Novartis Pharmaceuticals Corporation in May 2023.
  • "I am deeply honored and profoundly excited to witness the remarkable collaboration between MSAA, clinicians, academic researchers, industry partners, and SEQSTER for the Multiple Sclerosis Implementation Network.